Key Sessions
Facundo Batista, PhD
Evolving Novel Biologics In Vivo
Ragon Institute of MGH, MIT and Harvard
Andreas Hougaard Laustsen-Kiel, PhD
Snakebite Antivenoms En Route to Recombinant Biologics?
Technical University of Denmark
Susan Kalled, PhD
The Evolution of Antibody Therapies in Autoimmunity: From Toxic Immunosuppressant to Precision Modulator of Disease
Commit Biologics
Krista Kinneer
From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation
AstraZeneca
Main Conference Day 1 - PT (Pacific Time, GMT-08:00)
Main Conference Day 1 - PT (Pacific Time, GMT-08:00)
7:00am - 8:00am60 mins
Keynote Presentations - Livestream
Registration and Breakfast
8:00am - 8:05am5 mins
Keynote Presentations - Livestream
Co-Chairs' Welcome and Opening Remarks
- James Ernst, Ph.D. - Vice President, Development Sciences; Head of Protein Sciences & Technology, Xencor
- Paul Parren, PhD - Founder and CSO, Gyes BV
8:05am - 8:40am35 mins
Keynote Presentations - Livestream
Evolving Novel Biologics In Vivo
- Facundo Batista, PhD - Associate Director and Scientific Director, Ragon Institute of MGH, MIT and Harvard
8:40am - 9:15am35 mins
Keynote Presentations - Livestream
Snakebite Antivenoms En Route to Recombinant Biologics?
- Andreas Hougaard Laustsen-Kiel, PhD - Professor & Group Leader for Antibody Technologies, Technical University of Denmark
9:15am - 9:50am35 mins
Keynote Presentations - Livestream
The Evolution of Antibody Therapies in Autoimmunity: From Toxic Immunosuppressant to Precision Modulator of Disease
- Susan Kalled, PhD - Scientific Advisory Board Member, Commit Biologics
9:50am - 10:20am30 mins
Keynote Presentations - Livestream
Networking Refreshment Break
10:20am - 10:55am35 mins
Keynote Presentations - Livestream
From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation
- Krista Kinneer - Director, Oncology Translational Medicine, AstraZeneca
10:55am - 11:30am35 mins
Keynote Presentations - Livestream
Jim Huston Science Talent Award and Presentation:
- James Ernst, Ph.D. - Vice President, Development Sciences; Head of Protein Sciences & Technology, Xencor
11:30am - 12:05pm35 mins
Keynote Presentations - Livestream
Keynote Panel Discussion
12:05pm - 12:15pm10 mins
Keynote Presentations - Livestream
Transition to Scientific Luncheon Briefings
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 2
Engineering for Better Bispecifics: Introducing the B-Body® Platform
- Oren Beske, PhD - Head of Biologics, Twist Bioscience
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 3
Tips and Tricks in Speeding up Transient HEK293 and Transient/Stable CHO from 96 Well, 24 Well, 6 Well, 125mL-7L Optimum Growth Flasks
- Sam Ellis - Chief Executive Officer, Thomson Instrument Company
12:15pm - 1:15pm60 mins
Scientific Luncheon Briefing 5
From Bi- to Trispecific Antibodies: Reimagining the Next Generation of ADCs
- Dileep Pulukkunat, PhD - Senior Director of Antibody Discovery, Invenra
1:45pm - 2:15pm30 mins
Scientific Briefing 3
From Native Membrane Proteins to Complex Therapeutic Targets: Enabling Next-Generation Antibody Discovery
- Ivana Serrano, PhD - Field Application Scientist, Kactus Bio
1:45pm - 2:15pm30 mins
Scientific Briefing 4
Alloy Therapeutics Scientific Briefing
- Thomas Vincent - Senior Director of Antibody Technology, Alloy Therapeutics
2:25pm - 2:30pm5 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Co-Chairs' Remarks
- Brandon DeKosky, Ph.D. - Associate Professor of Chemical Engineering, MIT and The Ragon Institute
- Dima Kozakov, PhD - Professor, Stony Brook University
2:25pm - 2:30pm5 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Co-Chairs’ Remarks
- Jonathan Sockolosky, PhD - Co-founder and CEO, Macaw Therapeutics
- Sally Ward, PhD - Professor and Director, University of Southampton
2:30pm - 3:00pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Discovery of G protein-coupled Receptor Modulator Antibody Fragments
- Andrew Kruse - Professor of Biological Chemistry and Molecular Pharmacology, Harvard University
2:30pm - 3:00pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders
- Clarice Mengwen Zhang - Postdoctoral Fellow, Genentech
3:00pm - 3:30pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Late Breaking Presentation
3:00pm - 3:30pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
UTAC: Engineering a Bispecific that Converts Clinical Antibodies into Oral Formulations Using Active Retro-transcytosis
- Maurits Kleijnen - Chief Technology Officer, Intract Pharma Ltd
3:30pm - 4:00pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
High-throughput Re-exploration of Published Influenza Antibodies
- Nicholas Wu - Assistant Professor, Department of Biochemistry, University of Illinois at Urbana-Champaign
3:30pm - 4:00pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation
- Naoka Hironiwa - Chief Scientist, Chugai Pharmaceutical co. ltd.
4:00pm - 4:45pm45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
Networking Refreshment Break, Exhibit and Poster Viewing
4:45pm - 5:15pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation
- Isabel Elliott, PhD - Postdoctoral Researcher, University of Southampton
4:45pm - 5:15pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Tissue Specific Phenotypes and Functions of B-cells and Therapeutic Relevance
- Frances Lee, M.D - Professor of Medicine, Emory University
5:15pm - 5:45pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Computational Approaches for Antibody and TCR Modeling Design and Discovery
- Dzmitry Padhorny, PhD - Research Assistant, The University of Texas at Austin
5:15pm - 5:45pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Targeting IgE Responses
- Andre Limnander, PhD - Senior Director, Immunology & Inflammation, Regeneron
5:45pm - 6:15pm30 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Protecting AI-Generated Antibodies - Patent Strategy for a New Era
- Christopher Betti, PhD - Patent Lawyer, Morgan, Lewis & Bockius LLP
5:45pm - 6:15pm30 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Late Breaking Presentation
6:15pm - 7:45pm90 mins
Track 1: Emerging In Vitro Approaches to Antibody Discovery
Opening Night Networking Reception, Exhibits and Poster Viewing
6:15pm - 7:45pm90 mins
Track 2: Engineering Solutions for Accessing Difficult Targets
Opening Night Networking Reception, Exhibits and Poster Viewing
* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.